Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 20, 2026

A retiree says he'd have millions if he invested his Social Security in the S&P 500 — here's what he's missing

View original at finance.yahoo.com
A retiree says he'd have millions if he invested his Social Security in the S&P 500 — here's what he's missing Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • One-fifth of Social Security beneficiaries receive disability or young survivor benefits, not just retirement benefits.

    60% confidence

  • Mason's simple calculation comparing Social Security contributions to S&P 500 returns does not capture the full scope of a life, including disability protection, survivor benefits, and the social safety net function of Social Security.

    60% confidence

  • The risk of disability or premature death is greater than many people realize. Some 8% of recent entrants to the labor force will die before reaching the full retirement age, and many more will become disabled.

    60% confidence

  • Without Social Security, almost four in ten older adults would be living below the poverty line.

    60% confidence

  • The Social Security Act was designed to give some measure of protection to the average citizen and his family against the loss of a job and against poverty-ridden old age, even if it cannot insure 100% of the population against 100% of life's hazards.

    60% confidence

  • If his Social Security contributions had instead been invested in the S&P 500, the total would be in the millions, and his monthly drawdown would be many times greater than his actual Social Security benefit.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com
A retiree says he'd have millions if he invested his Social Security in the S&P 500 — here's what he's missing — Source | Via News | Finance Via News